TNF and T-cell non-Hodgkin lymphoma: The REFURBISH study was reported that the risk of getting T-cell non-Hodgkin’s lymphoma in IBD patients is higher during combinational therapy with compare to anti-TNF monotherapy [121] whereas the another cohort study delineate that even the ant--TNF monotherapy is associated with lymphoma formation in small number but have the higher statistical significant.